Zacks: Analysts Expect Bicycle Therapeutics plc (NASDAQ:BCYC) to Announce -$0.67 EPS

Wall Street brokerages expect that Bicycle Therapeutics plc (NASDAQ:BCYC) will post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Bicycle Therapeutics’ earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.79). Bicycle Therapeutics reported earnings of ($0.52) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 28.8%. The company is expected to announce its next earnings results on Thursday, November 4th.

On average, analysts expect that Bicycle Therapeutics will report full year earnings of ($2.82) per share for the current fiscal year, with EPS estimates ranging from ($3.36) to ($2.02). For the next year, analysts expect that the company will post earnings of ($3.01) per share, with EPS estimates ranging from ($4.61) to ($0.71). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that cover Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.79 million during the quarter, compared to analysts’ expectations of $2.51 million. Bicycle Therapeutics had a negative return on equity of 50.43% and a negative net margin of 546.62%.

A number of equities research analysts recently commented on BCYC shares. Roth Capital upped their price target on shares of Bicycle Therapeutics from $35.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, October 7th. JMP Securities upped their price target on shares of Bicycle Therapeutics from $53.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday. Piper Sandler upped their price target on shares of Bicycle Therapeutics from $46.00 to $76.00 and gave the company an “overweight” rating in a report on Friday, October 8th. B. Riley upped their price target on shares of Bicycle Therapeutics from $56.00 to $72.00 and gave the company a “buy” rating in a report on Friday, October 8th. Finally, Oppenheimer upped their price target on shares of Bicycle Therapeutics from $47.00 to $65.00 and gave the company an “outperform” rating in a report on Friday, October 8th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $67.22.

NASDAQ:BCYC traded up $3.46 during midday trading on Friday, reaching $59.84. 27,385 shares of the stock traded hands, compared to its average volume of 468,441. The company has a fifty day moving average of $38.74 and a 200 day moving average of $33.55. Bicycle Therapeutics has a 12 month low of $17.68 and a 12 month high of $56.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 9.36 and a current ratio of 9.36. The stock has a market capitalization of $1.53 billion, a P/E ratio of -19.99 and a beta of -0.42.

In related news, CEO Kevin Lee sold 1,808 shares of the firm’s stock in a transaction on Friday, August 27th. The stock was sold at an average price of $36.02, for a total value of $65,124.16. Following the completion of the sale, the chief executive officer now directly owns 246,893 shares in the company, valued at $8,893,085.86. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Lee Kalowski sold 7,950 shares of Bicycle Therapeutics stock in a transaction on Friday, August 27th. The stock was sold at an average price of $35.15, for a total value of $279,442.50. Following the sale, the chief financial officer now owns 550 shares of the company’s stock, valued at $19,332.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,474 shares of company stock valued at $1,859,850. Insiders own 17.90% of the company’s stock.

Hedge funds have recently modified their holdings of the company. WealthShield Partners LLC purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth about $27,000. Citigroup Inc. boosted its position in Bicycle Therapeutics by 107.8% in the second quarter. Citigroup Inc. now owns 1,066 shares of the company’s stock valued at $32,000 after buying an additional 553 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Bicycle Therapeutics in the first quarter valued at approximately $39,000. Personal CFO Solutions LLC acquired a new position in Bicycle Therapeutics in the second quarter valued at approximately $221,000. Finally, Geode Capital Management LLC acquired a new position in Bicycle Therapeutics in the second quarter valued at approximately $227,000. Institutional investors and hedge funds own 48.67% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

Featured Story: What is basic economics?

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.